• Careers
  • Contact Us
QED Therapeutics logo
  • Our
    Product
    • Targeting FGFR
    • TRUSELTIQ™
      (infigratinib)
    • Pipeline
    • Clinical Trials Currently Enrolling
  • Oncology
    • Cholangiocarcinoma
      (Bile Duct Cancer)
    • Urothelial Carcinoma
      (Bladder Cancer)
  • Achondroplasia
  • Grants and
    Sponsorships
    • Medical Professionals
    • Research Grants
    • Independent Medical Education (IME)
    • Patient-Focused Requests
    • Expanded Access Program
  • Who We Are
    • About QED Therapeutics
    • Our Team
    • BridgeBio
  • Resource
    Room
  • Menu
  • Sign Up to Stay Informed

    I am an HCP and would like to someone from QED to contact me.

  • Hidden
  • MM slash DD slash YYYY
  • :
     
  • *Required fields.

    Communication Agreement

    By completing this form and clicking the SUBMIT button, you understand and hereby consent to your personal information being stored on a database in the United States and accessible to QED Therapeutics for purposes such as marketing programs from QED Therapeutics, disseminating information about research from QED Therapeutics regarding infigratinib and related health conditions, and obtaining feedback about our products and services. You may request access to, removal, or correction of your personal information by sending an email to: [email protected]. Please review the full QED Therapeutics privacy policy for more information on your rights with respect to your personal information. If you are a resident of the European Union, please note that by submitting your information to QED through this form, you are expressly consenting to transfer of your personal data to the United States.

  • This field is for validation purposes and should be left unchanged.
  • Sign Up to Stay Informed

  • *Required fields.

    Communication Agreement

    By completing this form and clicking the SUBMIT button, you understand and hereby consent to your personal information being stored on a database in the United States and accessible to QED Therapeutics for purposes such as marketing programs from QED Therapeutics, disseminating information about research from QED Therapeutics regarding infigratinib and related health conditions, and obtaining feedback about our products and services. You may request access to, removal, or correction of your personal information by sending an email to: [email protected]. Please review the full QED Therapeutics privacy policy for more information on your rights with respect to your personal information. If you are a resident of the European Union, please note that by submitting your information to QED through this form, you are expressly consenting to transfer of your personal data to the United States.

  • This field is for validation purposes and should be left unchanged.

Contact Us

1800 Owens St, 12th Floor, San Francisco, CA 94158

1-877-280-5655

For additional information, reach out to [email protected]

Maps were disabled by the visitor on this site.

© 2022 QED Therapeutics, Inc. All rights reserved. US-QEDC-2100004 Privacy Policy | Terms of Use | Cookies Notice | Site Map

Scroll to top

Leaving Site

By selecting “Proceed” you will leave QEDTx.com and be directed to an external website.

Cancel Proceed